Literature DB >> 1736895

Polymorphism and proteolytic fragments of granulocyte membrane cofactor protein (MCP, CD46) of complement.

M Matsumoto1, T Seya, S Nagasawa.   

Abstract

Human granulocytes (polymorphonuclear leucocytes, PMN) possess a membrane cofactor protein (MCP, CD46), which is structurally and functionally distinct from the MCPs of other cell types: it shows a single broad band of 56-80 kDa (without the doublet pattern characteristic of MCP) on SDS/PAGE and has less affinity for complement component C3b. We purified PMN MCP using monoclonal antibodies in order to study the molecular differences between it and other MCPs. Several forms of PMN MCP with size heterogeneity were noted on SDS/PAGE and by immunoblotting. O-Glycanase treatment decreased this heterogeneity, yielding a fast-migrating component identical in position on SDS/PAGE to the O-glycanase-treated MCP of other cells. The cell-specific variation of MCP, therefore, arises from post-translational glycosylation and not from a difference in primary structure. The Factor I cofactor activity of PMN MCP was more efficient in cleaving the methylamine-treated complement components C4/C3 than was MCP from other cells, which shared a similar potency of cofactor activity on a weight basis. Two types of small-form PMN MCP were identified during purification. These were 42 kDa and 30 kDa in size; the former was recognized by M177 (a monoclonal antibody against the active site marker), possessed N-linked sugars [located on the short consensus repeats (SCRs)] but not O-linked ones (on the Ser/Thr-rich region), and retained cofactor activity for C3b/C4b cleavage, similar in potency to that of other MCPs. The functionally active soluble form of MCP was observed specifically in PMN. Protease inhibitors did not inhibit liberation of the fragments, although the generated fragments became susceptible to serine proteases. The findings show that the SCRs are the functional domain of MCP and that the MCP proteolysis found only in PMN may modulate the properties of PMN MCP. In conclusion, the structural features of PMN MCP largely reflect a variability in the O-linked sugars, and the decreased affinity for C3b may be in part attributable to proteolysis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1736895      PMCID: PMC1130712          DOI: 10.1042/bj2810493

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  36 in total

1.  Additional forms of human decay-accelerating factor (DAF).

Authors:  T Seya; T Farries; M Nickells; J P Atkinson
Journal:  J Immunol       Date:  1987-08-15       Impact factor: 5.422

2.  The PI-linked receptor FcRIII is released on stimulation of neutrophils.

Authors:  T W Huizinga; C E van der Schoot; C Jost; R Klaassen; M Kleijer; A E von dem Borne; D Roos; P A Tetteroo
Journal:  Nature       Date:  1988-06-16       Impact factor: 49.962

3.  Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane.

Authors:  D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-11       Impact factor: 11.205

4.  Distribution of membrane cofactor protein of complement on human peripheral blood cells. An altered form is found on granulocytes.

Authors:  T Seya; L L Ballard; N S Bora; V Kumar; W Cui; J P Atkinson
Journal:  Eur J Immunol       Date:  1988-08       Impact factor: 5.532

5.  Biochemical characterization of membrane cofactor protein of the complement system.

Authors:  L L Ballard; N S Bora; G H Yu; J P Atkinson
Journal:  J Immunol       Date:  1988-12-01       Impact factor: 5.422

6.  Alternative complement pathway-mediated myeloid cell cytotoxicity: repertoire of membrane factors participating in regulation of C3 deposition and cytolysis.

Authors:  M Matsumoto; Y Sugita; T Seya
Journal:  Eur J Immunol       Date:  1991-08       Impact factor: 5.532

7.  Decay accelerating factor of complement is anchored to cells by a C-terminal glycolipid.

Authors:  M E Medof; E I Walter; W L Roberts; R Haas; T L Rosenberry
Journal:  Biochemistry       Date:  1986-11-04       Impact factor: 3.162

8.  Functional properties of membrane cofactor protein of complement.

Authors:  T Seya; J P Atkinson
Journal:  Biochem J       Date:  1989-12-01       Impact factor: 3.857

9.  Loss of complement receptor type 1 (CR1) on ageing of erythrocytes. Studies of proteolytic release of the receptor.

Authors:  J Ripoche; R B Sim
Journal:  Biochem J       Date:  1986-05-01       Impact factor: 3.857

10.  Complement-mediated tumor cell damage induced by antibodies against membrane cofactor protein (MCP, CD46).

Authors:  T Seya; T Hara; M Matsumoto; Y Sugita; H Akedo
Journal:  J Exp Med       Date:  1990-12-01       Impact factor: 14.307

View more
  9 in total

1.  The fertilizing ability of human epididymal sperm.

Authors:  M Kitamura; K Matsumiya; M Namiki; T Hara; T Seya; A Okuyama
Journal:  J Assist Reprod Genet       Date:  1996-09       Impact factor: 3.412

2.  Distribution of membrane cofactor protein (MCP/CD46) on pig tissues. Relevance To xenotransplantation.

Authors:  J M Pérez de la Lastra; S M Hanna; B P Morgan
Journal:  Immunology       Date:  1999-09       Impact factor: 7.397

3.  The CD46 transmembrane domain is required for efficient formation of measles-virus-mediated syncytium.

Authors:  T Seya; M Kurita; K Iwata; Y Yanagi; K Tanaka; K Shida; M Hatanaka; M Matsumoto; S Jun; A Hirano; S Ueda; S Nagasawa
Journal:  Biochem J       Date:  1997-02-15       Impact factor: 3.857

4.  Modulation of complement regulatory function and measles virus receptor function by the serine-threonine-rich domains of membrane cofactor protein (CD46).

Authors:  K Iwata; T Seya; S Ueda; H Ariga; S Nagasawa
Journal:  Biochem J       Date:  1994-11-15       Impact factor: 3.857

5.  Blocking measles virus infection with a recombinant soluble form of, or monoclonal antibodies against, membrane cofactor protein of complement (CD46).

Authors:  T Seya; M Kurita; T Hara; K Iwata; T Semba; M Hatanaka; M Matsumoto; Y Yanagi; S Ueda; S Nagasawa
Journal:  Immunology       Date:  1995-04       Impact factor: 7.397

6.  Membrane cofactor protein (CD46) in seminal plasma is a prostasome-bound form with complement regulatory activity and measles virus neutralizing activity.

Authors:  M Kitamura; M Namiki; K Matsumiya; K Tanaka; M Matsumoto; T Hara; H Kiyohara; M Okabe; A Okuyama; T Seya
Journal:  Immunology       Date:  1995-04       Impact factor: 7.397

7.  Expression of membrane cofactor protein (MCP, CD46) in human liver diseases.

Authors:  N Kinugasa; T Higashi; K Nouso; H Nakatsukasa; Y Kobayashi; M Ishizaki; N Toshikuni; K Yoshida; S Uematsu; T Tsuji
Journal:  Br J Cancer       Date:  1999-08       Impact factor: 7.640

8.  Purification and characterization of a human membrane protein that activates the alternative complement pathway and allows the deposition of homologous complement C3.

Authors:  M Matsumoto; F Yamashita; K Iida; M Tomita; T Seya
Journal:  J Exp Med       Date:  1995-01-01       Impact factor: 14.307

9.  Levels of complement regulatory molecules in lung cancer: disappearance of the D17 epitope of CD55 in small-cell carcinoma.

Authors:  T Sakuma; K Kodama; T Hara; Y Eshita; N Shibata; M Matsumoto; T Seya; Y Mori
Journal:  Jpn J Cancer Res       Date:  1993-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.